Sugi Predict

Sugi Predict / Compounds / SCHEMBL668998

SCHEMBL668998

SCHEMBL668998

CC(C)(C)OC(=O)N[C@H]1C[C@@H](C(=O)O)C1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.73
▸ KMT2A Q03164 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ KDM1A O60341 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ CTSK P43235 2/20 0.46
▸ GAA P10253 2/20 0.45
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ EPHX2 P34913 1/20 0.43
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HSD11B1 P28845 1/20 0.42
▸ EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668997 1.00 BTK (0.73) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL758581 1.00 BTK (0.73) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL14376238 0.98 BTK (0.71) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL7486096 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL540505 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL182101 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL1299320 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL1662045 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL895759 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL2564638 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECH LIMITED (GB) 2026-05-21 — — US disclosed
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 — — WO disclosed
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2026-02-12 — — US disclosed
EP-4640280-A2 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-10-29 — — EP disclosed
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2025-10-02 — — US disclosed
EP-4384223-B1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-10-01 — — EP disclosed
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-05-01 — — US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 — — EP disclosed
US-12084467-B2 Therapeutic compounds for HIV virus infection GILEAD SCIENCES, INC. (US) 2024-09-10 — — US disclosed
US-20130296292-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-07 — — US disclosed
US-20130296291-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-07 — — US disclosed
US-20130296293-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-07 — — US disclosed
WO-2013157540-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF 富士フイルム株式会社 (JP) 2013-10-24 — — WO disclosed
WO-2013149121-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS CUBIST PHARMACEUTICALS, INC. (US) 2013-10-03 — — WO disclosed
EP-2606041-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-06-26 — — EP disclosed
WO-2012024363-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-23 — — WO disclosed
US-20090298894-A1 AMINO ACID COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2009-12-03 — — US disclosed
US-20090298894-A1 AMINO ACID COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2009-12-03 — — US disclosed
WO-2009131090-A1 AMINO ACID COMPOUND 旭化成ファーマ株式会社 (JP) 2009-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296293-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS BTD, BLVRB, PEPD BTK 885/4885KMT2A 3510/4885L3MBTL1 699/4885
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, KRAS, O60361 BTK 773/4885KMT2A 3265/4885L3MBTL1 549/4885
US-12084467-B2 Therapeutic compounds for HIV virus infection HAVCR2, MAVS, CD4 BTK 2515/4885KMT2A 3782/4885L3MBTL1 1303/4885
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 BTK 508/4885KMT2A 1711/4885L3MBTL1 201/4885
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS HAVCR2, CD47, CYTH3 BTK 397/4885KMT2A 3960/4885L3MBTL1 463/4885
US-20130296291-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS BTD, BLVRB, PEPD BTK 885/4885KMT2A 3510/4885L3MBTL1 699/4885
US-20090298894-A1 AMINO ACID COMPOUNDS S1PR1, S1PR2, S1PR5 BTK 1427/4885KMT2A 3063/4885L3MBTL1 1050/4885
US-20130296292-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS BTD, BLVRB, PEPD BTK 885/4885KMT2A 3510/4885L3MBTL1 699/4885
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 BTK 3727/4885KMT2A 1686/4885L3MBTL1 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.